secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-05-29T13:26:14+00:00
Accession:  0001437749-26-018819
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin ASCO data: Annamycin shows no cardiotoxicity at high cumulative doses
-------------------------------------------------------------------------------

- Pooled analysis of 90 patients: no significant LVEF change (mean diff -0.12%, p=0.84) across doses up to 2,970 mg/m².
- Independent Cleveland Clinic review confirms no drug-induced cardiotoxicity across ECGs, biomarkers, and adverse events.
- Phase 1b/2 AML study achieved 50% CR, 60% CRc, median overall survival 12.39 months; 50% of responders received transplant.
- Pivotal Phase 2b/3 MIRACLE trial unblinding of first 45 patients on track for June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926018819/0001437749-26-018819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926018819/mbrx20260529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer